Literature DB >> 1359831

Characterization of beta-adrenergic receptors in DiFi and HT-29 cells.

P W Abel1, W Zeng, D M Wildrick, M C Makoid, B M Boman.   

Abstract

The beta-adrenergic receptors present in two human colorectal adenocarcinoma cell lines were characterized by measuring specific binding of [125I]-cyanopindolol (CYP). Whole, cultured, DiFi (derived from a familial adenomatous polyposis [FAP] patient) and HT-29 cells were used in radioligand binding assays. Scatchard analysis of specific 125I-CYP binding gave KDS of 38.6 +/- 5.7 pM in DiFi cells and 54 +/- 9.1 pM in HT-29 cells. However, binding site density (Bmax) in the DiFi cells was greater than that in HT-29 cells. In DiFi cells, the kinetically determined KD was similar to that calculated from Scatchard analysis. Studies in DiFi cells of the displacement of specific 125I-CYP binding by nonselective (propranolol), beta 1-selective (metoprolol and atenolol), and beta 2-selective (ICI 118-551) antagonists revealed only a single class of beta 2-adrenergic receptors. This provides the first evidence that colorectal adenocarcinoma cell lines contain beta-adrenergic receptors and shows that only beta 2-adrenergic receptors are present in DiFi cells. Mechanisms possibly affecting beta-adrenergic-receptor expression in such cells are discussed in relation to colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359831

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer.

Authors:  Riccardo Giampieri; Mario Scartozzi; Michela Del Prete; Luca Faloppi; Maristella Bianconi; Francesca Ridolfi; Stefano Cascinu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

2.  The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists.

Authors:  Huayun Deng; Ye Fang
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.